Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CADL
Upturn stock ratingUpturn stock rating

Candel Therapeutics Inc (CADL)

Upturn stock ratingUpturn stock rating
$5.81
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/11/2025: CADL (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $22

1 Year Target Price $22

Analysts Price Target For last 52 week
$22 Target price
52w Low $3.79
Current$5.81
52w High $13.68

Analysis of Past Performance

Type Stock
Historic Profit 308.48%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/11/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 291.10M USD
Price to earnings Ratio -
1Y Target Price 22
Price to earnings Ratio -
1Y Target Price 22
Volume (30-day avg) 3
Beta -0.87
52 Weeks Range 3.79 - 13.68
Updated Date 07/13/2025
52 Weeks Range 3.79 - 13.68
Updated Date 07/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.33

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -32.31%
Return on Equity (TTM) -98.14%

Valuation

Trailing PE -
Forward PE 43.48
Enterprise Value 209844564
Price to Sales(TTM) 436.42
Enterprise Value 209844564
Price to Sales(TTM) 436.42
Enterprise Value to Revenue 821.98
Enterprise Value to EBITDA -0.01
Shares Outstanding 50102700
Shares Floating 40685880
Shares Outstanding 50102700
Shares Floating 40685880
Percent Insiders 17.53
Percent Institutions 40.72

ai summary icon Upturn AI SWOT

Candel Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Candel Therapeutics, Inc. (CADL) is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies to stimulate the patient's immune system against cancer. Founded in 2003, it has evolved from preclinical research to clinical trials, primarily focused on its two platforms: enGeneIC delivery system and oncolytic viral immunotherapy.

business area logo Core Business Areas

  • Oncolytic Viral Immunotherapy: Developing oncolytic viral immunotherapies using genetically engineered viruses to selectively infect and destroy cancer cells, while stimulating an immune response against the tumor.

leadership logo Leadership and Structure

Dr. Paul Peter Tak serves as the CEO. The company has a structured management team overseeing research and development, clinical operations, and corporate strategy.

Top Products and Market Share

overview logo Key Offerings

  • CAN-2409: An off-the-shelf adenovirus, CAN-2409, to induce an individualized, systemic anti-tumor immune response through in situ vaccination. Currently in clinical trials for non-small cell lung cancer, pancreatic cancer, and other solid tumors. Competitors include companies developing similar oncolytic viral therapies, such as Replimune (REPL), Oncolytics Biotech (ONCY), and Turnstone Biologics (TSBX).

Market Dynamics

industry overview logo Industry Overview

The oncolytic virus immunotherapy market is growing, driven by the potential to improve cancer treatment outcomes by harnessing the patient's immune system. Increased research funding and regulatory support are contributing to market expansion.

Positioning

Candel Therapeutics is positioned as a clinical-stage company focused on advancing its oncolytic viral immunotherapy platform, with CAN-2409 as its lead product candidate. The company aims to differentiate itself through its technology and clinical trial outcomes.

Total Addressable Market (TAM)

The TAM for oncolytic virus therapy is expected to reach billions of dollars. Candel's positioning focuses on specific cancer types where its therapies may offer a clinical advantage.

Upturn SWOT Analysis

Strengths

  • Proprietary oncolytic viral immunotherapy platform
  • Promising clinical trial data for CAN-2409
  • Experienced management team

Weaknesses

  • Limited financial resources relative to larger pharmaceutical companies
  • Reliance on successful clinical trial outcomes
  • High regulatory hurdles and development risks

Opportunities

  • Positive clinical trial results leading to regulatory approval and commercialization
  • Partnerships and collaborations with larger pharmaceutical companies
  • Expansion into new cancer indications

Threats

  • Clinical trial failures
  • Competition from other cancer therapies
  • Regulatory setbacks
  • Difficulties in raising capital

Competitors and Market Share

competitor logo Key Competitors

  • REPL
  • ONCY
  • TSBX

Competitive Landscape

Candel faces intense competition from companies with approved or late-stage oncolytic virus therapies. Success hinges on demonstrating superior efficacy and safety in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to being a clinical-stage company.

Future Projections: Future growth depends on the successful development and commercialization of CAN-2409. Analyst estimates vary depending on clinical trial outcomes.

Recent Initiatives: Focus on advancing CAN-2409 through clinical trials, including Phase 2 and Phase 3 studies. Actively seeking collaboration opportunities.

Summary

Candel Therapeutics is a clinical-stage biopharmaceutical company with a promising oncolytic viral immunotherapy platform. Its success depends on positive clinical trial results and successful commercialization of CAN-2409. Key challenges include competition, regulatory hurdles, and securing sufficient funding. While its pipeline is promising, the company's financial stability and reliance on successful clinical outcomes represent significant risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Candel Therapeutics Inc. SEC Filings
  • Candel Therapeutics Inc. Investor Relations
  • Industry Reports on Oncolytic Virus Immunotherapy

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Market data is based on estimates and may not be precise. Investment decisions should be based on your own due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Candel Therapeutics Inc

Exchange NASDAQ
Headquaters Needham, MA, United States
IPO Launch date 2021-07-27
President, CEO & Director Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 38
Full time employees 38

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the"enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.